Victory Capital Management
VRDN icon

Victory Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Victory Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Sell
81,629
-106,548
-57% -$1.72M ﹤0.01% 1720
2026
Q1 		$3.68M Sell
188,177
-38,640
-17% -$1.15M ﹤0.01% 1425
2025
Q4 		$7.06M Sell
226,817
-205,603
-48% -$5.64M ﹤0.01% 1171
2025
Q3 		$9.33M Sell
432,420
-132,370
-23% -$2.39M 0.01% 1128
2025
Q2 		$7.9M Buy
564,790
+11,940
+2% +$162K 0.01% 1179
2025
Q1 		$7.45M Buy
552,850
+142,410
+35% +$2.43M 0.01% 1156
2024
Q4 		$7.87M Buy
+410,440
New +$8.92M 0.01% 1150
2020
Q2 		– Sell
-512
Closed -$3K – 3280
2020
Q1 		$3K Buy
+512
New +$5.96K ﹤0.01% 3428
2019
Q4 		– Sell
-264
Closed -$3K – 3275
2019
Q3 		$3K Buy
+264
New +$5.84K ﹤0.01% 3580

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Victory Capital Management's VRDN Position: Q2 2026 in Review

Victory Capital Management reduced its Viridian Therapeutics (VRDN) stake by 57% in Q2 2026, selling an estimated $1.72M and leaving 81,629 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1720.

Victory Capital Management first reported a position in VRDN in Q3 2019 and has held it in 9 quarters since. The position peaked at $9.33M in Q3 2025. 215 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Victory Capital Management held 81,629 shares of Viridian Therapeutics worth $1.5M as of Q2 2026.
  • Victory Capital Management sold 106,548 Viridian Therapeutics shares in Q2 2026, an estimated $1.72M.
  • Viridian Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #1720 holding.
  • Victory Capital Management first reported a position in Viridian Therapeutics in Q3 2019 and has held it in 9 quarters since.
  • Victory Capital Management's Viridian Therapeutics position peaked at $9.33M in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.